News

Change of Registered Office

May 26, 2022

The directors of Proteome Sciences announce that the Company’s registered office address has changed to Coveham House, Downside Bridge Road, Cobham, Surrey KT11 3EP with immediate effect.

 

Result of Annual General Meeting (AGM)

May 16, 2022

The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 12.00 p.m. today, all resolutions were duly passed.

 

 

Annual General Meeting (AGM) Statement

May 16, 2022

Annual General Meeting (AGM) Statement

Substantial contract win for Proteome Sciences

May 12, 2022

Proteome Sciences is pleased to announce that the Company has secured a contract from a major US academic group. 

Director/PDMR Shareholding

April 26, 2022

The Company has received notification from Vulpes Investment Management Pte Ltd ("Vulpes") that on 22 April 2022 it purchased 183,812 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 4p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 67,475,006 Ordinary Shares, equivalent to 22.86% of Proteome Sciences' total issued share capital.

 

Director/PDMR Shareholding

April 21, 2022

The Company has received notification from Vulpes Investment Management Pte Ltd ("Vulpes") that on 19 April 2022 it purchased 1,465,000 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 4p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 67,291,194 Ordinary Shares, equivalent to 22.80% of Proteome Sciences' total issued share capital.

Investor Presentation.

April 11, 2022

Proteome Sciences plc is pleased to announce that Chief Executive Officer, Dr Mariola Soehngen, will provide a live presentation relating to the Company’s results for the year ended 31 December 2021 via the Investor Meet Company platform on 28 April 2021 at 10.30am BST.

Director Shareholding

April 01, 2022

The Company has been notified that the shareholding of Vulpes Life Sciences Fund ("Vulpes") remains unchanged at 65,826,194 ordinary shares, representing 22.3 per cent of the share capital, but that the holding has been transferred to a new custodian to hold the shares on Vulpes’ behalf.

 

Final results for the year ended 31 December 2021

March 31, 2022

The Company is pleased to announce its audited results for the year ended 31 December 2021.